Patents Represented by Attorney, Agent or Law Firm Patrick J. Halloran
-
Patent number: 8337846Abstract: Provided herein are compositions and methods for eliciting an immune response against Streptococcus pneumoniae. More particularly, the compositions and methods relate to immunogenic polypeptides, including fragments of PhtD and variants thereof, and nucleic acids, vectors and transfected cells that encode or express the polypeptides. Methods of making and using the immunogenic polypeptides are also described.Type: GrantFiled: July 23, 2008Date of Patent: December 25, 2012Assignee: Sanofi Pasteur LimitedInventors: Martina Ochs, Roger Brookes, Robert Charlebois, Jeremy Yethon
-
Patent number: 8299210Abstract: The present invention relates to reagents and methods for purifying pertussis toxin (PT).Type: GrantFiled: November 18, 2004Date of Patent: October 30, 2012Inventors: Andreas Jungbluth, Eberhard Schneider, Peter Wagner
-
Patent number: 8257717Abstract: The invention discloses immunogenic polypeptides comprising several MAGE-specific antigen epitopes selected from different (i.e. discrete) members of the MAGE protein family, nucleic acids coding therefor, recombinant viruses and/or cells comprising said nucleic acids, and compositions thereof. Methods for eliciting or inducing MAGE-specific immune responses utilizing the aforementioned immunogenic agents are also disclosed.Type: GrantFiled: October 27, 2010Date of Patent: September 4, 2012Assignees: Sanofi Pasteur Limited, Ludwig Institute for Cancer ResearchInventors: Neil Berinstein, James Tartaglia, John A. Tine, Philippe Moingeon, Thierry Boon-Falleur, Pierre Vander Bruggen
-
Patent number: 8236776Abstract: The present invention relates to a nucleic acid encoding a polypeptide and the use of the nucleic acid or polypeptide in preventing and/or treating cancer. The invention relates to improved vectors for the insertion and expression of foreign genes encoding tumor antigens for use in immunotherapeutic treatment of cancer. One such foreign DNA sequence is modified CEA nucleic acid.Type: GrantFiled: March 2, 2010Date of Patent: August 7, 2012Assignee: Sanofi Pasteur LimitedInventors: Mark Parrington, Linong Zhang, Benjamin Rovinski, Linda R. Gritz, Patricia Greenhalgh
-
Patent number: 8207314Abstract: The present invention relates to a nucleic acid encoding a polypeptide and the use of the nucleic acid or polypeptide in preventing and/or treating cancer. In particular, the invention relates to improved vectors for the insertion and expression of foreign genes encoding tumor antigens for use in immunotherapeutic treatment of cancer.Type: GrantFiled: April 15, 2004Date of Patent: June 26, 2012Assignee: Sanofi Pasteur LimitedInventors: Neil Berinstein, Scott Gallichan, Corey Lovitt, Mark Parrington, Laszlo Radvanyi, Devender Singh-Sandhu
-
Patent number: 8177177Abstract: An adjustable quick mounting system to be used with fixed position tree stands or similar support platforms, often found used for hunting or other outdoor activities. The adjustable mounting system includes a mounting base, detention hooks, and locking pin. The mounting base is connected securely to a tree or pole using a ratchet strap, cable or similar attachment device. The detention hooks are attached to tree stand or platform, preferably on the vertical support(s). The detention hooks are then engaged onto the mounting base by placing the open end of the detention hooks over the top portion of the mounting base. The mounting base has elongated slots manufactured into the design to allow the detention hooks to seat securely onto the base to prevent shifting of the base. The top surface of the mounting base has integrated tabs which are bent up and drilled to accept the locking pin.Type: GrantFiled: April 29, 2009Date of Patent: May 15, 2012Inventors: Robert Ehrig, Jason K. Werkheiser
-
Patent number: 8021664Abstract: The present invention relates to a nucleic acid encoding a polypeptide and the use of the nucleic acid or polypeptide in preventing and/or treating cancer. In particular, the invention relates to improved vectors for the insertion and expression of foreign genes encoding tumor antigens for use in immunotherapeutic treatment of cancer.Type: GrantFiled: April 15, 2004Date of Patent: September 20, 2011Assignee: Sanofi Pasteur LimitedInventors: Neil Berinstein, Scott Gallichan, Corey Lovitt, Mark Parrington, Artur Pedyczak, Laszlo Radvanyi, Devender Singh-Sandhu
-
Patent number: 8017590Abstract: An improved method of inducing and/or enhancing an immune response to a tumor antigen is disclosed. The method involves administering the tumor antigen, nucleic acid coding therefor, vectors and/or cells comprising said nucleic acid, or vaccines comprising the aforementioned to a lymphatic site.Type: GrantFiled: October 20, 2000Date of Patent: September 13, 2011Assignee: Sanofi Pasteur LimitedInventors: Neil Berinstein, James Tartaglia, Philippe Moingeon, Brian Barber
-
Patent number: 7851213Abstract: The present invention relates to a nucleic acid encoding a polypeptide and the use of the nucleic acid or polypeptide in preventing and/or treating cancer. In particular, the invention relates to improved vectors for the insertion and expression of foreign genes encoding tumor antigens for use in immunotherapeutic treatment of cancer.Type: GrantFiled: July 1, 2003Date of Patent: December 14, 2010Assignee: Sanofi Pasteur LimitedInventors: Neil Berinstein, Corey Lovitt, Mark Parrington, Artur Pedyczak, Laszlo Radvanyi, Scott Gallichan, Devender Singh-Sandhu, Raymond P. Oomen, Shi-Xian Cao
-
Patent number: 7851212Abstract: The invention discloses immunogenic polypeptides comprising several MAGE-specific antigen epitopes selected from different (i.e. discrete) members of the MAGE protein family, nucleic acids coding therefor, recombinant viruses and/or cells comprising said nucleic acids, and compositions thereof. Methods for eliciting or inducing MAGE-specific immune responses utilizing the aforementioned immunogenic agents are also disclosed.Type: GrantFiled: May 7, 2001Date of Patent: December 14, 2010Assignees: Sanofi Pasteur Limited, Ludwig Institute for Cancer ResearchInventors: Neil Berinstein, James Tartaglia, John A. Tine, Philippe Moingeon, Thierry Boon-Falleur, Pierre Vander Bruggen
-
Patent number: 7815934Abstract: A sequestering subunit comprising an aversive agent and a blocking agent, wherein the blocking agent substantially prevents release of the aversive agent from the sequestering subunit in the gastrointestinal tract for a time period that is greater than 24 hours; a composition comprising a sequestering subunit and a therapeutic agent in releasable form, wherein, optionally, the mechanical fragility of the sequestering subunit is the same as the mechanical fragility of the therapeutic agent in releasable form; a capsule or tablet comprising a sequestering subunit and a therapeutic agent; and a method of preventing abuse of a therapeutic agent.Type: GrantFiled: September 22, 2003Date of Patent: October 19, 2010Assignee: Alpharma Pharmaceuticals, LLCInventor: Garth Boehm
-
Patent number: 7790857Abstract: The technology relates to monoclonal antibodies useful in the identification of cancer cells. In one embodiment, mAbs with specificity for tumor antigens are provided. In one embodiment, methods for treating cancer using mAbs are provided. In another embodiment, methods for detecting cancerous cells are provided. In another embodiment, kits for detecting cancerous cells are provided.Type: GrantFiled: February 8, 2007Date of Patent: September 7, 2010Assignee: Sanofi Pasteur LimitedInventors: Neil Berinstein, Devender Singh-Sandhu, Corey Lovitt, Artur Pedyczak, Laszlo Radvanyi
-
Patent number: 7785609Abstract: Recombinant production of Hia protein, in full-length and N-terminally truncated forms, of non-typeable strains of Haemophilus influenzae, is described. The nucleic acid and deduced amino acid sequences of Hia genes of various strains of non-typeable and type c Haemophilus influenzae also are described.Type: GrantFiled: March 16, 2000Date of Patent: August 31, 2010Assignee: Sanofi Pasteur LimitedInventors: Sheena M. Loosmore, Yan-Ping Yang, Michel H. Klein
-
Patent number: 7786278Abstract: The present invention relates to a nucleic acid encoding a polypeptide and the use of the nucleic acid or polypeptide in preventing and/or treating cancer. The invention relates to improved vectors for the insertion and expression of foreign genes encoding tumor antigens for use in immunotherapeutic treatment of cancer. One such foreign DNA sequence is modified CEA nucleic acid.Type: GrantFiled: April 9, 2003Date of Patent: August 31, 2010Inventors: Mark Parrington, Linong Zhang, Benjamin Rovinski, Linda R. Gritz, Patricia Greenhalgh
-
Patent number: 6632438Abstract: Attenuated recombinant viruses containing DNA encoding an HCMV antigen, as well as methods and compositions employing the viruses, expression products therefrom, and antibodies generated from the viruses or expression products, are disclosed and claimed. The recombinant viruses can be NYVAC or ALVAC recombinant viruses. The recombinant viruses and gene products therefrom and antibodies generated by the viruses and gene products have several preventive, therapeutic and diagnostic uses. The DNA of the recombinant viruses can be used as probes or for generating PCR primers.Type: GrantFiled: July 26, 2001Date of Patent: October 14, 2003Assignee: Virogenetics CorporationInventors: Enzo Paoletti, Steven E. Pincus, William I. Cox, Elizabeth K. Kauffmann
-
Patent number: 6596279Abstract: Attenuated recombinant viruses containing DNA encoding an immunodeficiency virus and/or CTL antigen, as well as methods and compositions employing the viruses, expression products therefrom, and antibodies generated from the viruses or expression products, are disclosed and claimed. The recombinant viruses can be NYVAC or ALVAC recombinant viruses. The DNA can code for at least one of: HIV1gag(+pro)(IIIB), gp120(MN)(+transmembrane), nef(BRU)CTL, pol(IIIB)CTL, ELDKWA or LDKW epitopes, preferably HIV1gag(+pro)(IIIB), gp120(MN) (+transmembrane), two (2) nef(BRU)CTL and three (3) pol(IIIB)CTL etpitopes; or two ELDKWA in gp120 V3 or another region or in gp160. The two (2) nef(BRU)CTL and three (3) pol(IIIB)CTL epitopes are preferably CTL1, CTL2, pol1, pol2 and pol3. The recombinant viruses and gene products therefrom and antibodies generated by the viruses and gene products have several preventive, therapeutic and diagnostic uses.Type: GrantFiled: August 14, 1998Date of Patent: July 22, 2003Assignee: Virogenetics CorporationInventors: Enzo Paoletti, James Tartaglia, William I. Cox, Robert Gallo, Genoveffa Franchini
-
Patent number: 6538118Abstract: Heterologous lipidated proteins formed recombinantly are disclosed and claimed. The expression system can be E. coli. The heterologous lipidated protein has a leader sequence which does not naturally occur with the protein portion of the lipidated protein. The lipidated protein can have the Borrelia OspA leader sequence. The protein portion can be OspC, PspA, UreA, Ure B, or a fragment thereof. Methods and compositions for forming and employing the proteins are also disclosed and claimed.Type: GrantFiled: April 28, 1998Date of Patent: March 25, 2003Assignee: Connaught Laboratories, Inc.Inventors: Robert C. Huebner, Lorne F. Erdile, Donald J. Warakomski, Jr., Robert S. Becker, Maryann B. Gray, Derek J. Pyle